

# Tyler J Curiel

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/939286/publications.pdf>

Version: 2024-02-01

124  
papers

16,589  
citations

31902

53  
h-index

25716

108  
g-index

125  
all docs

125  
docs citations

125  
times ranked

21211  
citing authors

#	ARTICLE	IF	CITATIONS
1	Specific recruitment of regulatory T cells in ovarian carcinoma fosters immune privilege and predicts reduced survival. <i>Nature Medicine</i> , 2004, 10, 942-949.	15.2	4,442
2	Blockade of B7-H1 improves myeloid dendritic cell-mediated antitumor immunity. <i>Nature Medicine</i> , 2003, 9, 562-567.	15.2	1,157
3	Safety and Efficacy of Durvalumab (MEDI4736), an Anti-Programmed Cell Death Ligand-1 Immune Checkpoint Inhibitor, in Patients With Advanced Urothelial Bladder Cancer. <i>Journal of Clinical Oncology</i> , 2016, 34, 3119-3125.	0.8	755
4	B7-H4 expression identifies a novel suppressive macrophage population in human ovarian carcinoma. <i>Journal of Experimental Medicine</i> , 2006, 203, 871-881.	4.2	638
5	Stromal-derived factor-1 in human tumors recruits and alters the function of plasmacytoid precursor dendritic cells. <i>Nature Medicine</i> , 2001, 7, 1339-1346.	15.2	603
6	Interventions to Slow Aging in Humans: Are We Ready?. <i>Aging Cell</i> , 2015, 14, 497-510.	3.0	481
7	Tregs and rethinking cancer immunotherapy. <i>Journal of Clinical Investigation</i> , 2007, 117, 1167-1174.	3.9	464
8	Bone Marrow Is a Reservoir for CD4+CD25+ Regulatory T Cells that Traffic through CXCL12/CXCR4 Signals. <i>Cancer Research</i> , 2004, 64, 8451-8455.	0.4	395
9	CD73 on Tumor Cells Impairs Antitumor T-Cell Responses: A Novel Mechanism of Tumor-Induced Immune Suppression. <i>Cancer Research</i> , 2010, 70, 2245-2255.	0.4	361
10	Plasmacytoid Dendritic Cells Induce CD8+ Regulatory T Cells In Human Ovarian Carcinoma. <i>Cancer Research</i> , 2005, 65, 5020-5026.	0.4	346
11	CXCL12 and vascular endothelial growth factor synergistically induce neoangiogenesis in human ovarian cancers. <i>Cancer Research</i> , 2005, 65, 465-72.	0.4	295
12	Tumor-Intrinsic PD-L1 Signals Regulate Cell Growth, Pathogenesis, and Autophagy in Ovarian Cancer and Melanoma. <i>Cancer Research</i> , 2016, 76, 6964-6974.	0.4	294
13	Dendritic Cell Subsets Differentially Regulate Angiogenesis in Human Ovarian Cancer. <i>Cancer Research</i> , 2004, 64, 5535-5538.	0.4	270
14	Cross-Talk in the Innate Immune System: Neutrophils Instruct Recruitment and Activation of Dendritic Cells during Microbial Infection. <i>Journal of Immunology</i> , 2003, 171, 6052-6058.	0.4	262
15	Regulatory T cells and treatment of cancer. <i>Current Opinion in Immunology</i> , 2008, 20, 241-246.	2.4	246
16	Combined autophagy and HDAC inhibition. <i>Autophagy</i> , 2014, 10, 1403-1414.	4.3	240
17	CD73 has distinct roles in nonhematopoietic and hematopoietic cells to promote tumor growth in mice. <i>Journal of Clinical Investigation</i> , 2011, 121, 2371-2382.	3.9	221
18	Regulatory T Cells in Ovarian Cancer: Biology and Therapeutic Potential. <i>American Journal of Reproductive Immunology</i> , 2005, 54, 369-377.	1.2	197

#	ARTICLE	IF	CITATIONS
19	IL-2 immunotoxin denileukin diftitox reduces regulatory T cells and enhances vaccine-mediated T-cell immunity. <i>Blood</i> , 2007, 110, 3192-3201.	0.6	177
20	Tumor Cell-Independent Estrogen Signaling Drives Disease Progression through Mobilization of Myeloid-Derived Suppressor Cells. <i>Cancer Discovery</i> , 2017, 7, 72-85.	7.7	153
21	LIVER ALLOTRANSPLANTATION AFTER EXTRACORPOREAL HEPATIC SUPPORT WITH TRANSGENIC (hCD55/hCD59) PORCINE LIVERS. <i>Transplantation</i> , 2000, 69, 272.	0.5	143
22	Cytokine Receptor CXCR4 Mediates Estrogen-Independent Tumorigenesis, Metastasis, and Resistance to Endocrine Therapy in Human Breast Cancer. <i>Cancer Research</i> , 2011, 71, 603-613.	0.4	140
23	Tumour DDR1 promotes collagen fibre alignment to instigate immune exclusion. <i>Nature</i> , 2021, 599, 673-678.	13.7	139
24	Programmed death ligand 1 signals in cancer cells. <i>Nature Reviews Cancer</i> , 2022, 22, 174-189.	12.8	133
25	Suppressive IL-17A <sup>+</sup> Foxp3 <sup>+</sup> and ex-Th17 IL-17A <sup>neg</sup> Foxp3 <sup>+</sup> Treg cells are a source of tumour-associated Treg cells. <i>Nature Communications</i> , 2017, 8, 14649.	5.8	128
26	Macrophage-Derived Dendritic Cells Have Strong Th1-Polarizing Potential Mediated by $\hat{I}^2$ -Chemokines Rather Than IL-12. <i>Journal of Immunology</i> , 2000, 165, 4388-4396.	0.4	121
27	B7-H1-Dependent Sex-Related Differences in Tumor Immunity and Immunotherapy Responses. <i>Journal of Immunology</i> , 2010, 185, 2747-2753.	0.4	120
28	Attenuation of RNA polymerase II pausing mitigates BRCA1-associated R-loop accumulation and tumorigenesis. <i>Nature Communications</i> , 2017, 8, 15908.	5.8	118
29	Antiestrogenic Glyceollins Suppress Human Breast and Ovarian Carcinoma Tumorigenesis. <i>Clinical Cancer Research</i> , 2006, 12, 7159-7164.	3.2	107
30	A randomized control trial to establish the feasibility and safety of rapamycin treatment in an older human cohort: Immunological, physical performance, and cognitive effects. <i>Experimental Gerontology</i> , 2018, 105, 53-69.	1.2	107
31	After the Storm - Health Care Infrastructure in Post-Katrina New Orleans. <i>New England Journal of Medicine</i> , 2006, 354, 1549-1552.	13.9	100
32	Mitigating Age-Related Immune Dysfunction Heightens the Efficacy of Tumor Immunotherapy in Aged Mice. <i>Cancer Research</i> , 2012, 72, 2089-2099.	0.4	100
33	Chronic mTOR inhibition in mice with rapamycin alters T, B, myeloid, and innate lymphoid cells and gut flora and prolongs life of immune-deficient mice. <i>Aging Cell</i> , 2015, 14, 945-956.	3.0	94
34	Peptides Identified through Phage Display Direct Immunogenic Antigen to Dendritic Cells. <i>Journal of Immunology</i> , 2004, 172, 7425-7431.	0.4	92
35	Host miR155 Promotes Tumor Growth through a Myeloid-Derived Suppressor Cell-Dependent Mechanism. <i>Cancer Research</i> , 2015, 75, 519-531.	0.4	92
36	Tumor cell-intrinsic PD-L1 promotes tumor-initiating cell generation and functions in melanoma and ovarian cancer. <i>Signal Transduction and Targeted Therapy</i> , 2016, 1, .	7.1	83

#	ARTICLE	IF	CITATIONS
37	Female Gender Is Associated With a Worse Survival After Radical Cystectomy for Urothelial Carcinoma of the Bladder: A Competing Risk Analysis. <i>Urology</i> , 2014, 83, 863-868.	0.5	82
38	NK Cells Help To Induce CD8+ T-Cell Immunity against <i>Toxoplasma gondii</i> in the Absence of CD4+ T Cells. <i>Infection and Immunity</i> , 2005, 73, 4913-4921.	1.0	80
39	mTORC1 and p53. <i>Cell Cycle</i> , 2013, 12, 20-25.	1.3	79
40	Myeloid Cells That Impair Immunotherapy Are Restored in Melanomas with Acquired Resistance to BRAF Inhibitors. <i>Cancer Research</i> , 2017, 77, 1599-1610.	0.4	79
41	Follicle-Stimulating Hormone Receptor Is Expressed by Most Ovarian Cancer Subtypes and Is a Safe and Effective Immunotherapeutic Target. <i>Clinical Cancer Research</i> , 2017, 23, 441-453.	3.2	77
42	HIV-Specific Cellular and Humoral Immune Responses in Primary HIV Infection. <i>AIDS Research and Human Retroviruses</i> , 1996, 12, 1129-1140.	0.5	74
43	Dendritic cells generated in the presence of GM-CSF plus IL-15 prime potent CD8+ Tc1 responses in vivo. <i>European Journal of Immunology</i> , 2004, 34, 66-73.	1.6	70
44	Targeting regulatory T cells. <i>Targeted Oncology</i> , 2012, 7, 15-28.	1.7	67
45	Adipose PD-L1 Modulates PD-1/PD-L1 Checkpoint Blockade Immunotherapy Efficacy in Breast Cancer. <i>Oncotarget</i> , 2018, 7, e1500107.	2.1	66
46	A phosphotyrosine switch determines the antitumor activity of ER $\beta$ . <i>Journal of Clinical Investigation</i> , 2014, 124, 3378-3390.	3.9	65
47	Vorinostat and hydroxychloroquine improve immunity and inhibit autophagy in metastatic colorectal cancer. <i>Oncotarget</i> , 2016, 7, 59087-59097.	0.8	65
48	Oncogenic BRAFV600E Governs Regulatory T-cell Recruitment during Melanoma Tumorigenesis. <i>Cancer Research</i> , 2018, 78, 5038-5049.	0.4	64
49	eRapa Restores a Normal Life Span in a FAP Mouse Model. <i>Cancer Prevention Research</i> , 2014, 7, 169-178.	0.7	63
50	TGF- $\beta$ -mediated silencing of genomic organizer SATB1 promotes Tfh cell differentiation and formation of intra-tumoral tertiary lymphoid structures. <i>Immunity</i> , 2022, 55, 115-128.e9.	6.6	62
51	Aged regulatory T cells protect from autoimmune inflammation despite reduced STAT3 activation and decreased constraint of IL-17 producing T cells. <i>Aging Cell</i> , 2012, 11, 509-519.	3.0	61
52	Intratumoral CD56bright natural killer cells are associated with improved survival in bladder cancer. <i>Oncotarget</i> , 2018, 9, 36492-36502.	0.8	60
53	Inhibition of Human Immunodeficiency Virus-1 Production Resulting from Transduction with a Retrovirus Containing an HIV-Regulated Diphtheria Toxin A Chain Gene. <i>Human Gene Therapy</i> , 1992, 3, 461-469.	1.4	59
54	Altering regulatory T cell function in cancer immunotherapy: a novel means to boost the efficacy of cancer vaccines. <i>Frontiers in Bioscience - Landmark</i> , 2009, Volume, 1761.	3.0	59

#	ARTICLE	IF	CITATIONS
55	Toxoplasma gondii-Infected Human Myeloid Dendritic Cells Induce T-Lymphocyte Dysfunction and Contact-Dependent Apoptosis. <i>Infection and Immunity</i> , 2002, 70, 1750-1760.	1.0	57
56	Optimization of Immunotherapy in Elderly Cancer Patients. <i>Critical Reviews in Oncogenesis</i> , 2013, 18, 573-583.	0.2	55
57	p38 Mitogen-Activated Protein Kinase Stimulates Estrogen-Mediated Transcription and Proliferation through the Phosphorylation and Potentiation of the p160 Coactivator Glucocorticoid Receptor-Interacting Protein 1. <i>Molecular Endocrinology</i> , 2006, 20, 971-983.	3.7	54
58	Ovarian cancer immunogenicity is governed by a narrow subset of progenitor tissue-resident memory T <sub>H</sub> cells. <i>Cancer Cell</i> , 2022, 40, 545-557.e13.	7.7	53
59	Regulatory T-cell development: is Foxp3 the decider?. <i>Nature Medicine</i> , 2007, 13, 250-253.	15.2	52
60	Resident memory CD8 <sup>+</sup> T <sub>H</sub> cells in regional lymph nodes mediate immunity to metastatic melanoma. <i>Immunity</i> , 2021, 54, 2117-2132.e7.	6.6	50
61	Pyridinylimidazole p38 mitogen-activated protein kinase inhibitors block intracellular Toxoplasma gondii replication. <i>International Journal for Parasitology</i> , 2002, 32, 969-977.	1.3	46
62	Progressive increases in serum catalase activity in advancing human immunodeficiency virus infection. <i>Free Radical Biology and Medicine</i> , 1992, 13, 143-149.	1.3	44
63	Tumor cell-intrinsic CD274/PD-L1: A novel metabolic balancing act with clinical potential. <i>Autophagy</i> , 2017, 13, 987-988.	4.3	44
64	Antigen-Specific Immunity and Cross-Priming by Epithelial Ovarian Carcinoma-Induced CD11b <sup>+</sup> Gr-1 <sup>+</sup> Cells. <i>Journal of Immunology</i> , 2010, 184, 6151-6160.	0.4	42
65	Therapeutic Targeting of PELP1 Prevents Ovarian Cancer Growth and Metastasis. <i>Clinical Cancer Research</i> , 2011, 17, 2250-2259.	3.2	42
66	Immunotherapy: A useful strategy to help combat multidrug resistance. <i>Drug Resistance Updates</i> , 2012, 15, 106-113.	6.5	42
67	Identification of a novel mitogen-activated protein kinase in Toxoplasma gondii. <i>International Journal for Parasitology</i> , 2004, 34, 1245-1254.	1.3	40
68	High efficiency transduction of dendritic cells by adenoviral vectors targeted to DC-SIGN. <i>Cancer Biology and Therapy</i> , 2005, 4, 289-294.	1.5	37
69	Graft-versus-Host Disease Is Enhanced by Selective CD73 Blockade in Mice. <i>PLoS ONE</i> , 2013, 8, e58397.	1.1	37
70	Toxoplasma gondii Expresses Two Mitogen-Activated Protein Kinase Genes That Represent Distinct Protozoan Subfamilies. <i>Journal of Molecular Evolution</i> , 2007, 64, 4-14.	0.8	36
71	Long-Term Inhibition of Clinical and Laboratory Human Immunodeficiency Virus Strains in Human T-Cell Lines Containing an HIV-Regulated Diphtheria Toxin A Chain Gene. <i>Human Gene Therapy</i> , 1993, 4, 741-747.	1.4	34
72	Immune-Stimulatory Effects of Rapamycin Are Mediated by Stimulation of Antitumor $\gamma\delta$ T Cells. <i>Cancer Research</i> , 2016, 76, 5970-5982.	0.4	33

#	ARTICLE	IF	CITATIONS
73	Considerations for successful cancer immunotherapy in aged hosts. <i>Experimental Gerontology</i> , 2018, 107, 27-36.	1.2	33
74	Therapeutic utility of natural estrogen receptor beta agonists on ovarian cancer. <i>Oncotarget</i> , 2017, 8, 50002-50014.	0.8	32
75	Murder or Mercy? Hurricane Katrina and the Need for Disaster Training. <i>New England Journal of Medicine</i> , 2006, 355, 2067-2069.	13.9	29
76	Parasite Mitogen-Activated Protein Kinases as Drug Discovery Targets to Treat Human Protozoan Pathogens. <i>Journal of Signal Transduction</i> , 2011, 2011, 1-16.	2.0	29
77	p53 and rapamycin are additive. <i>Oncotarget</i> , 2015, 6, 15802-15813.	0.8	29
78	Drugs Designed To Inhibit Human p38 Mitogen-Activated Protein Kinase Activation Treat <i>Toxoplasma gondii</i> and <i>Encephalitozoon cuniculi</i> Infection. <i>Antimicrobial Agents and Chemotherapy</i> , 2007, 51, 4324-4328.	1.4	27
79	Human p38 mitogen-activated protein kinase inhibitor drugs inhibit <i>Plasmodium falciparum</i> replication. <i>Experimental Parasitology</i> , 2011, 128, 170-175.	0.5	27
80	Percutaneous BCG enhances innate effector antitumor cytotoxicity during treatment of bladder cancer: a translational clinical trial. <i>Oncotarget</i> , 2019, 8, 1614857.	2.1	27
81	Sequential Intravesical Mitomycin plus Bacillus Calmette-Guérin for Non-Muscle-Invasive Urothelial Bladder Carcinoma: Translational and Phase I Clinical Trial. <i>Clinical Cancer Research</i> , 2015, 21, 303-311.	3.2	26
82	Age effects of distinct immune checkpoint blockade treatments in a mouse melanoma model. <i>Experimental Gerontology</i> , 2018, 105, 146-154.	1.2	26
83	Bladder cancer cell-intrinsic PD-L1 signals promote mTOR and autophagy activation that can be inhibited to improve cytotoxic chemotherapy. <i>Cancer Medicine</i> , 2021, 10, 2137-2152.	1.3	26
84	HIV-Regulated Diphtheria Toxin A Chain Gene Confers Long-Term Protection Against HIV Type 1 Infection in the Human Promonocytic Cell Line U937. <i>Human Gene Therapy</i> , 1995, 6, 1437-1445.	1.4	25
85	Trends in immunoconjugate and ligand-receptor based targeting development for cancer therapy. <i>Expert Opinion on Drug Delivery</i> , 2008, 5, 87-103.	2.4	23
86	Immunotherapy for Ovarian Cancer. <i>Current Treatment Options in Oncology</i> , 2015, 16, 317.	1.3	23
87	Tumor Intrinsic PD-L1 Promotes DNA Repair in Distinct Cancers and Suppresses PARP Inhibitor-Induced Synthetic Lethality. <i>Cancer Research</i> , 2022, 82, 2156-2170.	0.4	23
88	Immune Therapy for Ovarian Cancer: Promise and Pitfalls. <i>International Reviews of Immunology</i> , 2011, 30, 102-119.	1.5	21
89	Tumor-extrinsic discoidin domain receptor 1 promotes mammary tumor growth by regulating adipose stromal interleukin 6 production in mice. <i>Journal of Biological Chemistry</i> , 2018, 293, 2841-2849.	1.6	21
90	CD122-Selective IL2 Complexes Reduce Immunosuppression, Promote Treg Fragility, and Sensitize Tumor Response to PD-L1 Blockade. <i>Cancer Research</i> , 2020, 80, 5063-5075.	0.4	21

#	ARTICLE	IF	CITATIONS
91	IgA-Dominated Humoral Immune Responses Govern Patients' Outcome in Endometrial Cancer. <i>Cancer Research</i> , 2022, 82, 859-871.	0.4	21
92	Rapamycin Prevents Surgery-Induced Immune Dysfunction in Patients with Bladder Cancer. <i>Cancer Immunology Research</i> , 2019, 7, 466-475.	1.6	19
93	Immunologic principles and immunotherapeutic approaches in ovarian cancer. <i>Hematology/Oncology Clinics of North America</i> , 2003, 17, 1051-1073.	0.9	18
94	Aging-associated B7-1 <sup>hi</sup> B cells enhance anti-tumor immunity via Th1 and Th17 induction. <i>Aging Cell</i> , 2012, 11, 128-138.	3.0	18
95	Prevention of Carcinogen and Inflammation-Induced Dermal Cancer by Oral Rapamycin Includes Reducing Genetic Damage. <i>Cancer Prevention Research</i> , 2015, 8, 400-409.	0.7	18
96	Biphasic Rapamycin Effects in Lymphoma and Carcinoma Treatment. <i>Cancer Research</i> , 2017, 77, 520-531.	0.4	18
97	Rapamycin enhances BCG-specific $\gamma$ T cells during intravesical BCG therapy for non-muscle invasive bladder cancer: a randomized, double-blind study. , 2021, 9, e001941.		18
98	Estrogen receptor beta signaling in CD8 <sup>+</sup> T cells boosts T cell receptor activation and antitumor immunity through a phosphotyrosine switch. , 2021, 9, e001932.		17
99	Tyrosine phosphorylation regulates ER $\alpha$ ubiquitination, protein turnover, and inhibition of breast cancer. <i>Oncotarget</i> , 0, 7, 42585-42597.	0.8	16
100	Genetic ablation of adipocyte PD-L1 reduces tumor growth but accentuates obesity-associated inflammation. , 2020, 8, e000964.		15
101	TgMAPK1 is a <i>Toxoplasma gondii</i> MAP kinase that hijacks host MKK3 signals to regulate virulence and interferon- $\gamma$ -mediated nitric oxide production. <i>Experimental Parasitology</i> , 2013, 134, 389-399.	0.5	13
102	PPAR $\gamma$ inhibition boosts efficacy of PD-L1 Checkpoint Blockade Immunotherapy against Murine Melanoma in a sexually dimorphic manner. <i>International Journal of Biological Sciences</i> , 2020, 16, 1526-1535.	2.6	12
103	CD122-directed interleukin-2 treatment mechanisms in bladder cancer differ from $\gamma$ PD-L1 and include tissue-selective $\gamma$ T cell activation. , 2021, 9, e002051.		12
104	Tumor immunotherapy: inching toward the finish line. <i>Journal of Clinical Investigation</i> , 2002, 109, 311-312.	3.9	11
105	$\gamma$ T Cells Support Antigen-Specific $\gamma$ T cell-Mediated Antitumor Responses during BCG Treatment for Bladder Cancer. <i>Cancer Immunology Research</i> , 2021, 9, 1491-1503.	1.6	9
106	Modulation of autophagy: a Phase II study of vorinostat plus hydroxychloroquine versus regorafenib in chemotherapy-refractory metastatic colorectal cancer (mCRC). <i>British Journal of Cancer</i> , 2022, 127, 1153-1161.	2.9	7
107	IFN $\gamma$ Augments Clinical Efficacy of Regulatory T-cell Depletion with Denileukin Diftitox in Ovarian Cancer. <i>Clinical Cancer Research</i> , 2021, 27, 3661-3673.	3.2	6
108	Immune checkpoint expression and relationships to anti-PD-L1 immune checkpoint blockade cancer immunotherapy efficacy in aged versus young mice. <i>Aging and Cancer</i> , 2022, 3, 68-83.	0.5	5

#	ARTICLE	IF	CITATIONS
109	Pharmacologic Tumor PDL1 Depletion with Cefepime or Ceftazidime Promotes DNA Damage and Sensitivity to DNA-Damaging Agents. <i>International Journal of Molecular Sciences</i> , 2022, 23, 5129.	1.8	4
110	Manipulating T regulatory cells in cancer immunotherapy. <i>Expert Review of Dermatology</i> , 2006, 1, 589-597.	0.3	3
111	Historical Perspectives and Current Trends in Cancer Immunotherapy. , 2013, , 3-15.		3
112	Alignment of single-cell trajectories by tuMap enables high-resolution quantitative comparison of cancer samples. <i>Cell Systems</i> , 2021, , .	2.9	3
113	Abstract LB-259: Interferon- $\gamma$ enhances clinical benefits of regulatory T cell depletion in ovarian cancer through direct T cell effects and by inducing bystander IL-6. <i>Cancer Research</i> , 2014, 74, LB-259-LB-259.	0.4	2
114	Selective delipidation of Mycobacterium bovis BCG retains antitumor efficacy against non-muscle invasive bladder cancer. <i>Cancer Immunology, Immunotherapy</i> , 2023, 72, 125-136.	2.0	2
115	CD122-targeted interleukin-2 and $\gamma$ -PD-L1 treat bladder cancer and melanoma via distinct mechanisms, including CD122-driven natural killer cell maturation. <i>Oncimmunology</i> , 2021, 10, 2006529.	2.1	1
116	900 $\mu$ M...Depleting non-canonical, cell-intrinsic PD-L1 signals induces synthetic lethality to small molecule DNA damage response inhibitors in an immune independent and dependent manner. , 2021, 9, A944-A944.		1
117	242 $\mu$ M...Pharmacologic tumor PD-L1 depletion with chlorambucil treats ovarian cancer and melanomas in a tumor PD-L1-dependent manner and renders $\gamma$ -PD-L1-resistant tumors $\gamma$ -PD-L1-sensitive. , 2021, 9, A261-A261.		1
118	Abstract LB160: PD-L1-expressing B cells promote murine breast cancer development and mediate the response to anti-PD-L1 immune checkpoint inhibitor to upregulate B-cell CD86 and inhibit tumor growth. , 2021, , .		0
119	Regulatory T Cells in Cancer. , 2012, , 147-173.		0
120	Miscellaneous Approaches and Considerations: TLR Agonists and Other Inflammatory Agents, Anti-Chemokine Agents, Infectious Agents, Tumor Stroma Targeting, Age and Sex Effects, and Miscellaneous Small Molecules. , 2013, , 399-424.		0
121	Targeted Toxins in Cancer Immunotherapy. , 2013, , 377-396.		0
122	Managing Regulatory T Cells to Improve Cancer Immunotherapy. , 2013, , 281-314.		0
123	Chronic Mechanistic Target of Rapamycin Inhibition: Preventing Cancer to Delay Aging or Vice Versa?. , 2018, , 1-18.		0
124	Chronic Mechanistic Target of Rapamycin Inhibition: Preventing Cancer to Delay Aging or Vice Versa?. , 2020, , 111-128.		0